Press Releases

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Mar. 14, 2019-- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Data Safety Monitoring Board (DSMB) has recommended the

REDWOOD CITY, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will

Financing Led by Abingworth; Andrew Sinclair , Partner, to Join Soleno’s Board Funding to Support Ongoing Phase III Clinical Program (DESTINY PWS) for DCCR in Prader-Willi Syndrome REDWOOD CITY, Calif. , Dec. 19, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.

DCCR treatment resulted in statistically significant decreases in body fat in subjects with Prader-Willi Syndrome REDWOOD CITY, Calif. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the

REDWOOD CITY, Calif. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the third

Oral presentation on DCCR’s mechanism of action in treating hyperphagia Poster presentation on DCCR’s safety profile and implications for PWS Phase III study design REDWOOD CITY, Calif. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical

Pharmacokinetic data supports once-daily dosing Long-term use of DCCR not associated with compromised glycemic control REDWOOD CITY, Calif. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the

REDWOOD CITY, Calif. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will conduct

REDWOOD CITY, Calif. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases will present two poster presentations from studies of Soleno’s lead product candidate,

Amendment Lowers Minimum Age Inclusion Criteria to Four Years, from Eight Years, to Better Reflect Demographics of PWS Population Top-line Data from Phase III Trial Expected in First Half of 2019 REDWOOD CITY, Calif. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.